Spots Global Cancer Trial Database for stage i renal cell cancer
Every month we try and update this database with for stage i renal cell cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer | NCT00002473 | Kidney Cancer | conventional su... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer | NCT00899860 | Kidney Cancer | - 120 Years | Wake Forest University Health Sciences | ||
| Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | NCT00087022 | Kidney Cancer | girentuximab placebo | 18 Years - 120 Years | Heidelberg Pharma AG | |
| Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | NCT00087022 | Kidney Cancer | girentuximab placebo | 18 Years - 120 Years | Heidelberg Pharma AG | |
| Vaccine Therapy in Treating Patients With Kidney Cancer | NCT00096629 | Kidney Cancer | human prostate-... mouse prostate-... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | NCT00727532 | Hereditary Clea... Kidney Cancer | Sorafenib | 18 Years - 120 Years | Northwestern University | |
| DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE | NCT00900536 | Kidney Cancer | mutation analys... polymorphism an... protein express... immunohistochem... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies | NCT01243359 | Clear Cell Rena... Recurrent Renal... Stage I Renal C... Stage II Renal ... Stage III Renal... Stage IV Renal ... Unspecified Adu... | sunitinib malat... bevacizumab pharmacological... laboratory biom... fluorine F 18 f... positron emissi... computed tomogr... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer | NCT00849186 | Kidney Cancer | sunitinib malat... neoadjuvant the... therapeutic con... | 18 Years - | Roswell Park Cancer Institute | |
| Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors | NCT00445757 | Kidney Cancer | conventional su... stereotactic ra... | 18 Years - | Case Comprehensive Cancer Center | |
| Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | NCT00436410 | Adrenocortical ... Breast Cancer Colorectal Canc... Gastrointestina... Kidney Cancer Liver Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Sarcoma | colloidal gold-... electron micros... pharmacological... conventional su... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE | NCT00900536 | Kidney Cancer | mutation analys... polymorphism an... protein express... immunohistochem... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Kidney Cancer | NCT00096629 | Kidney Cancer | human prostate-... mouse prostate-... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer | NCT02664883 | Healthy Subject Metastatic Rena... Recurrent Renal... Stage I Renal C... Stage II Renal ... Stage III Renal... | Computed Tomogr... Cytology Specim... Laboratory Biom... Magnetic Resona... | 25 Years - | University of Southern California | |
| Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | NCT02885649 | Clear Cell Rena... Stage I Renal C... | Enzalutamide Laboratory Biom... Nephrectomy | 18 Years - | Rutgers, The State University of New Jersey | |
| Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer | NCT04473781 | Stage I Renal C... Stage II Renal ... | Interstitial Ra... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer | NCT00849186 | Kidney Cancer | sunitinib malat... neoadjuvant the... therapeutic con... | 18 Years - | Roswell Park Cancer Institute | |
| Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer | NCT00908739 | Kidney Cancer | gene expression... immunohistochem... laboratory biom... | - | Case Comprehensive Cancer Center | |
| sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | NCT02767921 | Infiltrating Bl... Recurrent Bladd... Stage I Prostat... Stage I Renal C... Stage II Bladde... Stage II Renal ... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage III Renal... | Cytology Specim... Laboratory Biom... Radical Cystect... Recombinant Eph... Therapeutic Con... | 18 Years - | University of Southern California | |
| Bryostatin 1 In Treating Patients With Progressive Kidney Cancer | NCT00005056 | Kidney Cancer | bryostatin 1 | 18 Years - | National Cancer Institute (NCI) | |
| Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors | NCT01281488 | Recurrent Renal... Stage I Renal C... Stage II Renal ... | fluorescence im... laparoscopic su... indocyanine gre... | 18 Years - | City of Hope Medical Center | |
| S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery | NCT01120249 | Kidney Cancer | everolimus placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants | NCT00900276 | Bladder Cancer Kidney Cancer Transitional Ce... Urethral Cancer | immunologic tec... laboratory biom... mass spectromet... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer | NCT00004890 | Drug Extravasat... Kidney Cancer | aldesleukin Biomed 101 | 18 Years - | National Cancer Institute (NCI) | |
| Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors | NCT00445757 | Kidney Cancer | conventional su... stereotactic ra... | 18 Years - | Case Comprehensive Cancer Center | |
| Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial | NCT06432036 | Stage I Renal C... Stage II Renal ... | Angiogram Biospecimen Col... Computed Tomogr... Radioembolizati... Single Photon E... Survey Administ... Yttrium Y 90 Gl... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | NCT02885649 | Clear Cell Rena... Stage I Renal C... | Enzalutamide Laboratory Biom... Nephrectomy | 18 Years - | Rutgers, The State University of New Jersey | |
| Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer | NCT00908739 | Kidney Cancer | gene expression... immunohistochem... laboratory biom... | - | Case Comprehensive Cancer Center | |
| Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer | NCT00004890 | Drug Extravasat... Kidney Cancer | aldesleukin Biomed 101 | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | NCT00335556 | Childhood Renal... Clear Cell Rena... Clear Cell Sarc... Papillary Renal... Rhabdoid Tumor ... Stage I Renal C... Stage I Renal W... Stage II Renal ... Stage II Renal ... Stage III Renal... Stage III Renal... Stage IV Renal ... Stage IV Renal ... | Doxorubicin Hyd... Irinotecan Hydr... Conventional Su... Cyclophosphamid... Etoposide Carboplatin Dactinomycin Vincristine Sul... Radiation Thera... Laboratory Biom... | - 29 Years | Children's Oncology Group | |
| S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery | NCT01120249 | Kidney Cancer | everolimus placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Radiosurgery in Treating Patients With Kidney Tumors | NCT00458484 | Kidney Cancer | stereotactic ra... Renal Biopsy Serum Blood Mar... | 18 Years - | Case Comprehensive Cancer Center | |
| Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial | NCT06432036 | Stage I Renal C... Stage II Renal ... | Angiogram Biospecimen Col... Computed Tomogr... Radioembolizati... Single Photon E... Survey Administ... Yttrium Y 90 Gl... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer | NCT02664883 | Healthy Subject Metastatic Rena... Recurrent Renal... Stage I Renal C... Stage II Renal ... Stage III Renal... | Computed Tomogr... Cytology Specim... Laboratory Biom... Magnetic Resona... | 25 Years - | University of Southern California | |
| Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors | NCT02526511 | Stage I Renal C... Stage II Renal ... Stage III Renal... Stage IV Renal ... | Arterial Spin L... Dynamic Contras... Dynamic Suscept... Perfusion Magne... | 18 Years - | Rutgers, The State University of New Jersey | |
| Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors | NCT02526511 | Stage I Renal C... Stage II Renal ... Stage III Renal... Stage IV Renal ... | Arterial Spin L... Dynamic Contras... Dynamic Suscept... Perfusion Magne... | 18 Years - | Rutgers, The State University of New Jersey | |
| Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer | NCT00492258 | Kidney Cancer | sorafenib tosyl... adjuvant therap... | 18 Years - | National Cancer Institute (NCI) | |
| Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer | NCT04473781 | Stage I Renal C... Stage II Renal ... | Interstitial Ra... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | NCT01158521 | Clear Cell Rena... Stage I Renal C... Stage II Renal ... Stage III Renal... | pazopanib hydro... therapeutic con... | 18 Years - | Case Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
